Non Alcoholic Steatohepatitis Clinical Trials Market Report: Market Size & Forecast 2026

NASH is a progressive liver condition closely linked to obesity, type 2 diabetes, and metabolic syndrome, affecting a significant and growing portion of the global adult population. The clinical trials market specifically measures spending on protocol design, patient recruitment, site management, biomarker and imaging services, endpoint adjudication, and regulatory consulting across all trial phases. Demand is fueled by the absence of approved therapies for much of the preceding decade, prompting a sustained wave of interventional studies exploring mechanisms ranging from FXR agonism and PPAR modulation to FGF21 analogues and ASK1 inhibition. Trial sponsors face particular challenges including slow enrollment, variable histologic endpoints, and the need for long follow-up periods to capture fibrosis regression or resolution of NASH without worsening of fibrosis.

• •Clinical trial spending in this space has grown from approximately $2.92 billion in 2024 toward a projected $3.72 billion in 2026, reflecting accelerating pipeline activity.
• •The broader NASH treatment market, by contrast, is estimated between $7.5 billion and $9.9 billion in 2025, indicating the clinical trials segment represents a meaningful sub-sector.
• •Trial design complexity is a defining characteristic, with many late-stage studies requiring paired liver biopsies 12-18 months apart, significantly inflating per-patient costs and timelines.

The dominant catalyst is the large and expanding NASH patient pool, estimates suggest over 400 million people globally carry the underlying NAFLD condition, with a substantial fraction progressing to NASH and advanced fibrosis. Regulatory pathways have matured considerably, with health authorities issuing guidance on acceptable surrogate endpoints and accelerated approval frameworks specifically for NASH therapies, reducing development risk and encouraging investment. Advances in non-invasive diagnostic tools, including elastography, MRI-based fat-fraction quantification, and serum biomarker panels, are lowering trial costs and expanding the addressable patient population eligible for enrollment. Additionally, the recent approval of a small number of pharmacologic agents for NASH in select markets has validated the commercial opportunity and spurred further late-stage investment.

• •Rising prevalence of metabolic disease globally, driven by obesity, sedentary lifestyles, and aging populations, expands the eligible clinical trial patient pool year over year.
• •Regulatory evolution, including the acceptance of fibrosis improvement as a surrogate endpoint, has shortened path-to-approach and attracted a broader set of development-stage sponsors.
• •Technological progress in non-invasive diagnostic modalities is reducing reliance on costly and burdensome liver biopsy, enabling larger, more efficient trials.

The market is segmented by trial phase, therapeutic modality, endpoint type, and geography, with North America historically accounting for the largest share of trial activity due to dense specialist infrastructure and favorable regulatory conditions. Europe, particularly Western Europe, follows as a strong secondary hub, leveraging integrated healthcare systems that facilitate patient identification and follow-up. The Asia-Pacific region is emerging as a fast-growing segment as CRO capacity expands, clinical trial costs are lower, and NAFLD prevalence rises sharply across middle-income economies. Latin America and the Middle East/Africa represent smaller but expanding markets as local clinical trial ecosystems develop and multinational sponsors seek geographic diversification of enrollment sites.

• •North America leads in trial volume and per-patient spending, supported by established hepatology networks, academic medical centers, and proactive regulatory engagement.
• •Asia-Pacific is the fastest-growing regional segment, with expanding CRO infrastructure, cost-competitive site operations, and rising disease prevalence driving increased trial placement.
• •Phase III and Phase IV trials dominate spending within the segment, reflecting the late-stage nature of most current NASH drug development programs.

Who are the notable companies in the industry?

The competitive structure of the NASH clinical trials market is moderately consolidated among a relatively small number of large, full-service global contract research organizations alongside a broader tier of mid-size and specialized CROs with focused liver-disease or metabolic-disease expertise. The market is characterized by a vertically integrated supply chain in which large CROs offer end-to-end capabilities spanning protocol development, site selection, patient recruitment, central laboratory services, imaging core labs, and regulatory consulting. Smaller specialty players compete on niche capabilities such as fibrosis-scoring readout services, patient-identification algorithms leveraging electronic health record data, and regional site networks in underpenetrated geographies. Capacity is concentrated in North America and Western Europe, though major global CROs have been steadily expanding Asia-Pacific footprint to serve sponsors seeking more cost-efficient trial execution.

• •The market sits between oligopolistic and fragmented: a core group of global full-service CROs holds the majority of large-budget NASH trial contracts, while a longer tail of specialized and regional providers competes on specific therapeutic expertise or geographic niches.
• •Service offerings span the full clinical trial value chain, with competitive differentiation centered on patient-recruitment speed, biometrics capability, liver-imaging core lab infrastructure, and regulatory strategy for NASH-specific endpoints.
• •Global capacity is weighted toward North America and Western Europe, with CRO providers increasingly establishing direct operational footprints or partnership networks in the Asia-Pacific region to capture cost and patient-pool advantages.

What are the recent trends and outlook?

Looking forward, the market is expected to sustain high single-digit to low double-digit expansion through the early 2030s as first-in-class and best-in-class NASH therapies advance through pivotal trials and seek regulatory approval in additional territories. A significant trend is the increasing use of real-world evidence and synthetic control arms to reduce trial size and duration, a development accelerated by regulatory receptivity to alternative trial designs. Decentralized and hybrid trial models are gaining adoption as sponsors seek to reduce geographic barriers to enrollment and improve patient retention in long-duration fibrosis studies. Rising investment in companion diagnostics and precision-enrollment strategies is expected to further reshape trial design, potentially increasing per-patient service complexity while overall timelines compress as validated endpoints and biomarkers become standardized.

• •The projected 21.85% CAGR positions the NASH clinical trials market among the faster-growing segments within the broader clinical research services industry.
• •Decentralized and hybrid trial delivery models are expected to gain share as sponsors seek to broaden enrollment and reduce dropout rates in multi-year fibrosis studies.
• •Long-term market sustainability depends on continued pipeline productivity; successful launches of multiple approved agents would eventually shift spending from late-stage trials toward Phase IV and post-marketing surveillance activities.